{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T08:06:14Z","timestamp":1776413174417,"version":"3.51.2"},"reference-count":24,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2025,7,12]],"date-time":"2025-07-12T00:00:00Z","timestamp":1752278400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Novo Nordisk, Inc"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Journal of Medical Economics"],"published-print":{"date-parts":[[2025,12,31]]},"DOI":"10.1080\/13696998.2025.2526282","type":"journal-article","created":{"date-parts":[[2025,6,28]],"date-time":"2025-06-28T01:30:11Z","timestamp":1751074211000},"page":"1075-1085","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":3,"title":["Impact of semaglutide 2.4\u2009mg on healthcare resource utilization and medical costs in patients with atherosclerotic cardiovascular disease in the United States (SHINE-ASCVD)"],"prefix":"10.1080","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3390-0182","authenticated-orcid":false,"given":"Wojciech","family":"Michalak","sequence":"first","affiliation":[{"name":"Novo Nordisk, Inc","place":["Plainsboro, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-8219-3900","authenticated-orcid":false,"given":"Zhenxiang","family":"Zhao","sequence":"additional","affiliation":[{"name":"Novo Nordisk, Inc","place":["Plainsboro, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6464-9958","authenticated-orcid":false,"given":"Mads","family":"Faurby","sequence":"additional","affiliation":[{"name":"Novo Nordisk, Inc","place":["Plainsboro, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-6804-6470","authenticated-orcid":false,"given":"Sara","family":"Alvarez","sequence":"additional","affiliation":[{"name":"Novo Nordisk, Inc","place":["Plainsboro, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9912-5994","authenticated-orcid":false,"given":"Angela","family":"Fitch","sequence":"additional","affiliation":[{"name":"knownwell","place":["Boston, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2025,7,12]]},"reference":[{"key":"e_1_3_5_2_1","unstructured":"American Heart Association Atherosclerotic cardiovascular disease (ASCVD). 2025. Available from: https:\/\/www.heart.org\/en\/professional\/quality-improvement\/ascvd."},{"key":"e_1_3_5_3_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-024-02324-w"},{"key":"e_1_3_5_4_1","unstructured":"Khavjou O Phelps D Leib A. Projections of cardiovascular disease prevalence and costs: 2015\u20132035. 2015. Available from: https:\/\/www.heart.org\/-\/media\/Files\/Get-Involved\/Advocacy\/CVD-Predictions-Through-2035.pdf."},{"key":"e_1_3_5_5_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000001256"},{"key":"e_1_3_5_6_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12872-023-03518-y"},{"key":"e_1_3_5_7_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.cir.67.5.968"},{"key":"e_1_3_5_8_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000973"},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2307563"},{"key":"e_1_3_5_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(25)00864-2"},{"key":"e_1_3_5_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/osp4.737"},{"key":"e_1_3_5_12_1","doi-asserted-by":"publisher","DOI":"10.1080\/00325481.2025.2482274"},{"key":"e_1_3_5_13_1","unstructured":"Komodo Health Solutions Imputing allowed amounts development and validation of an encounter-level allowed amount imputation model. 2023. Available from: https:\/\/knowledge.komodohealth.com\/hubfs\/2023\/Komodo_Imputing_Allowed_Amounts_White_Paper.pdf."},{"key":"e_1_3_5_14_1","doi-asserted-by":"publisher","DOI":"10.18637\/jss.v042.i08"},{"key":"e_1_3_5_15_1","doi-asserted-by":"publisher","DOI":"10.18637\/jss.v111.i09"},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-023-02051-8"},{"key":"e_1_3_5_17_1","unstructured":"Michalak W Nordisk N Boame N et\u00a0al. Effects of semaglutide 2.4\u2009mg on healthcare costs in patients with obesity and heart failure. Presented at: Obesity Week 2024 San Antonio TX. Poster-086. 2024. Available from: https:\/\/tos.planion.com\/Web.User\/AbstractDet?ACCOUNT=TOS&ABSID=1105766&CONF=OW2024&ssoOverride=OFF&CKEY=B16I7I888."},{"key":"e_1_3_5_18_1","unstructured":"Novo Nordisk Inc. NovoCare\u00ae Pharmacy. 2025. https:\/\/www.novocare.com\/obesity\/products\/wegovy\/get-product.html."},{"key":"e_1_3_5_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-024-01678-4"},{"key":"e_1_3_5_20_1","unstructured":"Michalak W Nordisk N Boame N et\u00a0al. Effects of semaglutide 2.4\u2009mg on healthcare costs in patients with obesity and heart failure. Presented at: Obesity Week 2024 San Antonio TX. Oral-112. 2024. Available from: https:\/\/tos.planion.com\/Web.User\/AbstractDet?ACCOUNT=TOS&ABSID=1105766&CONF=OW2024&ssoOverride=OFF&CKEY=B16I7I888."},{"key":"e_1_3_5_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2024.04.041"},{"key":"e_1_3_5_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14890"},{"key":"e_1_3_5_23_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2032183"},{"key":"e_1_3_5_24_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.publhealth.20.1.125"},{"key":"e_1_3_5_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/obr.13885"}],"container-title":["Journal of Medical Economics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13696998.2025.2526282","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T10:47:25Z","timestamp":1766400445000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13696998.2025.2526282"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,12]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12,31]]}},"alternative-id":["10.1080\/13696998.2025.2526282"],"URL":"https:\/\/doi.org\/10.1080\/13696998.2025.2526282","relation":{},"ISSN":["1369-6998","1941-837X"],"issn-type":[{"value":"1369-6998","type":"print"},{"value":"1941-837X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,12]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2025-05-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-13","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-25","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-12","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}